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Abstract: Adipokines, cytokines derived from adipose tissue, not only herald and confirm fat tissue as the largest 
endocrine organ but are also associated with a number of pathological states including obesity, insulin resistance and 
diabetes. There is a growing body of research on the role of adipokines in blood pressure regulation and development 
of hypertension. One of these adipokines, adiponectin, is especially interesting, given that it has numerous beneficial 
effects which include increasing insulin sensitivity and antiatherogenic and anti-inflammatory effects. In recent years, 
there has been a number of studies examining its possibly protective role in hypertension. In this narrative review we 
summarize the evidence on the association of adiponectin and polymorphism of the gene which encodes it with blood 
pressure levels and risk of hypertension, which might provide ideas for future research of adiponectin as a biomarker 
and potential therapeutic target in this condition. 
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A link between hypertension and obesity has been 
known to exist for several decades, with an abundance 
of evidence coming from early epidemiologic studies. 
This link has become especially interesting since, in 
recent decades, adipose tissue has started to be more 
frequently seen not as just an inert energy reservoir, but 
as the largest endocrine organ which secretes a large 
number of chemical compounds.1 Cook et al. isolated 
the first fat tissue-derived active protein, adipsin (now 
known as factor D), in 1987, and Friedman et al. 
discovered the first major adipokine, leptin (product of 
ob/ob gene), in 1994, finally confirming the hypothesis 
of fat tissue as an active endocrine organ.2, 3 Since then, 
more than 600 of such adipose tissue-derived 
compounds have been isolated.4 These compounds, 
called adipokines or adipocytokines, have a variety of 
biological functions including effects on satiety, insulin 
sensitivity, energy balance and inflammatory, 
atherogenic and immune effects.1, 4 Thus the theory of 
adipokines as homeostasis regulators was formed 
which says that different adipokines have differing and 
frequently mutually opposite functions which results in 
their balance being perceived as physiological 
homeostasis, while any disbalance might lead to 
pathological states.5 
This narrative review will examine the association of 
adiponectin, a major adipokine and a frequent topic of 
research, with blood pressure regulation and 
hypertension. We aim to present its discovery, structure 
and mechanisms of action, followed by its effect on 
blood pressure and, finally, its role in disease based on 
recent clinical studies in hypertension. 
 
 
The discovery and structure of adiponectin 
Adiponectin is a protein secreted almost exclusively by 
adipose tissue and, with a plasma concentration of 5 to 
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30 mg/L, it is the most abundant adipokine in human 
plasma.6 It was isolated from murine adipocytes in 
1995 by Scherer et al., who named it Acrp30 
(adipocyte complement-related protein of 30 kDa) due 
to homology with complement factor C1.7 At 
approximately the same time it was also independently 
discovered by three more groups: 1. Hu et al. who also 
isolated it from murine adipocytes and named it 
AdipoQ, 2. Maeda et al. who scanned the human 
adipocyte complementary DNA library and named it 
Apm1 (adipose most abundant gene transcript 1), and 
3. Nakano et al. who extracted and purified it from 
human plasma and named it GBP28 (gelatin-binding 
protein 28).8-10 Today it is customary to use the term 
adiponectin for the human protein and Acrp30 for the 
corresponding protein in mice with 85% homology.11 
Structurally, adiponectin consists of a globular domain 
on a collagen stalk and is a member of the C1q 
family.12 It is a protein built from 244 amino acids with 
four domains: 1. the amino-terminal signal sequence, 2. 
the variable region, 3. the collagen domain and 4. the 
carboxy-terminal globular domain. This form is termed 
the full-length form.11, 13 There are also smaller mass 
forms formed by leucocyte esterase cleavage on at least 
4 locations, which are termed globular forms (globular 
adiponectin). Globular adiponectin makes up around 
1% of all adiponectin forms and is probably implicated 
in fatty acid oxidation, but its other functions are still 
not completely elucidated.11, 13-15    
However, monomeric adiponectin is found only in 
adipocytes, while homo-oligomers consisting of 
trimeric adiponectin (low molecular weight, LMW 
adiponectin) as a basic building block are found in 
plasma. Aside from the LMW form, hexamers (middle 
molecular weight, MMW) and oligomers with 12, or 
more units (high molecular weight, HMW) are also 
found.11, 16 Some authors postulate that the most 
abundant form is the HMW octadecamer.17 
 
 
Receptors and general mechanisms of action of 
adiponectin 
Kadowaki et al. isolated the cDNA of the first 
adiponectin receptor, AdipoR1 (chromosomal location 
of the gene at 1p36.13-q4) in 2003 by screening for 
potential globular adiponectin binding sites.18 Further 
search for homologous genes found only one suitable 
gene with over 66% amino-acid sequence homology 
which was termed AdipoR2 (chromosomal location of 
the gene at 12p13.31).18 AdipoR1 and AdipoR2 belong 
to the Progesteron and AdipoQ Receptor (PAQR) 
superfamily, consist of seven transmembrane domains 
and are topologically integral membrane proteins with 
intracellular N-terminus and extracellular C-terminus, 
which is contrary to topology of all other G-protein 
coupled receptors.11 Aside from the heptahelical 
transmembrane domain, these two receptors share tri 
short amino acid motifs characteristic for this 
superfamily: 1. Ex2-3Nx3N/H, 2. Sx3HxnD and 3. 
Hx3H. Even though the first Scathchard plots showed 
that AdipoR1 is exclusively a receptor for globular 
adiponectin and AdipoR2 for full-length adiponectin 
(trimers and multimers), it has been shown in later 
studies that both forms probably bind to both receptors, 
but with different affinities – globular adiponectin has a 
high affinity for AdipoR1, while globular adiponectin 
and the full-length form have intermediate affinity for 
AdipoR2.11, 16, 18 Although it is practically certain that 
both receptors are present in many different tissues, 
there are differences in their distributions, with 
AdipoR1 being primarily expressed in skeletal muscle 
and AdipoR2 in liver.11 Mechanistically, adiponectin 
acts through   at   least   three   different   signal  
pathways: 1. adenosine monophosphate kinase 
(AMPK) activation, 2. peroxisome proliferator 
activated receptor α (PPARα) activation and 3. 
simulation of ceramidase activity. Full-length forms 
bind to AdipoR1 and stimulate AMPK phosphorylation 
in skeletal muscle and liver, while globular adiponectin 
stimulates phosphorylation only in skeletal muscle. 
These pathways require calcium and calmodulin-
dependent protein kinase kinase (Ca2+/CaMMKKβ), 
adenosine monophosphate and liver kinase B1 also 
known as serine/threonine kinase 11 (AMP/LKB1). 
Activation of this signal pathway in the liver decreases 
the expression of gluconeogenesis enzymes 
(phosphoenolpyruvate carboxylase and glucose-6-
phosphatase).16, 19 It is fairly certain that, aside from 
these three signal pathways, there is at least one 
additional one, probably mediated by a separate 
receptor. Proof of this is that adiponectin increases IL-6 
expression in macrophages via NF-kappa B activation 
independent of AdipoR1 and AdipoR2.20 Hug et al. 
identified a possible third receptor – T-cadherin coded 
by CDH123.21 However, T-cadherin is an extracellular 
protein anchored to glycosil phosphate inositol, and it 
does not have an intracellular domain, so it is probably 
only a binding protein or a co-receptor for adiponectin. 
Interestingly, only eukaryotic adiponectin binds to T-
cadherin, which implies necessary post-translational 
modifications. Also, Hug et al showed that only 
hexameric and HMW forms of adiponectin, and not the 
trimer and globular form, bind to T-cadherin.21 
Adiponectin is not bound in the cardiac tissue of mice 
who do not express T-cadherin, so Denzel et al. 
showed that its expression is necessary for the 
cardioprotective effects of adiponectin.22 
 
 
Effect on blood pressure 
A number of studies examined the association of 
adiponectin in physiology of blood pressure regulation-
related pathology and pathophysiology, mainly 
hypertension. It is known today that adiponectin and 
blood pressure are related via at least three 
mechanisms: 1. the NO system and endothelial 
dysfunction, 2. the renin-angiotensin system and 3. 
central effect mediated via the sympathetic nervous 
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system.23 Experiments measuring brachial blood flow 
following reactive hyperemia showed that plasma 
adiponectin concentration correlated with endothelial 
response.24 Other studies showed that adiponectin-
deficient mice have impaired endothelial response, i.e. 
decreased vasodilatatory response and decreased nitrate 
and nitrite concentration. Tan et al. demonstrated that 
in diabetic subjects, hypoadiponectinemia is associated 
with endothelial dysfunction which was remedied after 
adiponectin administration.24-27 
Both full-length adiponectin and the globular form 
increase NO concentration, while the former also 
stimulates eNOS phosphorylation at Ser1179 location, 
thereby increasing its activity.28, 29 Both adiponectin 
receptors are present in endothelial cells, and a 
decrease in expression of either one of them lowers NO 
production.27, 30 Even though the exact mechanisms are 
not yet clearly elucidated, it is believed that several 
pathways including phosphatidylinositol 3-kinase, 
AMPK, cyclooxygenase-2 (COX-2), AAPL1 and 
Hsp90 are involved in signaling pathways via which 
adiponectin affects NO concentration.31 Research has 
shown that the AMPK and COX-2 pathways 
undeniably play a large role in the association of 
adiponectin, endothelial dysfunction and blood 
pressure regulation. Adiponectin has been shown to 
activate the AMPK pathway which may mediate 
phosphorylation downstream of adiponectin signaling 
and in turn stimulate NO synthesis and 
bioavailability.31 Additionally, it has been proven that 
adiponectin might mediate endothelial function via a 
different pathway from AMPK, i.e. the COX-2 
pathway, and that recombinant adiponectin treatment 
increases COX-2 expression in cultured endothelial 
cells, which in turn promotes endothelial cell function 
via activation of Akt-dependent COX-2 signaling 
pathway.31 Another mechanism which may be involved 
is adiponectin-mediated decrease in the endothelial 
expression of adhesion molecules and in scavenger 
receptor type A-1 in macrophages, which is associated 
with inflammatory modulation and possibly lower risk 
of atherosclerosis.31 Increased angiotensin II plasma 
concentration increases blood pressure, while 
dysregulation of the renin-angiotensin-aldosterone  
system  leads to hypertension.32, 33 This fact coupled 
with the knowledge that both angiotensin II receptor 
blockers and adiponectin may lead to increased insulin 
sensitivity prompted research into the relationship of 
adiponectin and angiotensin. Continuous chronic 
angiotensin II infusion leads to decreased adiponectin 
plasma concentration and increased free radical activity 
in rats.34, 35 It is interesting that this decrease is not 
dependent on angiotensin II receptor blockade (at least 
not subtype 2, which is the target of angiotensin 
blockers) and that this happens prior to the decrease in 
blood pressure. Increase in free radical concentration 
might be the cause of decrease in plasma adiponectin 
concentrations, especially when it is known that 
hydrogen peroxide inhibits adiponectin expression.36 
The mechanism of this process is almost certainly post-
translational, because the concentration of adiponectin 
messenger RNA is left unchanged.37 There are hints 
that PPARγ might be the missing link between 
adiponectin and angiotensin II, because of increase in 
PPARγ activity after administration of angiotensin II 
blocker telmisartan. Additionally, research showed that 
another angiotensin II blocker, irbesartan, increases 
plasma adiponectin concentration and that this increase 
could  be prevented  with selective PPARγ 
antagonists.38, 39 This evidence demonstrates the 
mechanism of this arm of adiponectin-blood pressure 
relationship, but also imply that angiotensin II receptor 
blockers might be even more potent than was thought 
before and also that, in addition to antihypertensive and 
insulin-sensitizing effects, they may also independently 
increase the plasma adiponectin concentration. 
The sympathetic nervous system consists of neurons 
which regulate a variety of body functions and it is 
responsible for stress-response.40 Different pathological 
states, such as obesity and metabolic syndrome, are 
associated with higher sympathetic nervous system 
activity, i.e. overflow of sympathetic activity.41 In these 
cases, increased sympathetic workflow leads to 
increased heart frequency and total peripheral 
resistance, which may lead to hypertension. 
Experimental studies in mice showed that cold 
stimulation, which simulates sympathetic activity, 
leads to decreased transcription and adiponectin 
secretion and that this process is reversible with 
epinephrine inhibitors.42 Also, administration of β3 
receptor (adipose tissue adrenergic receptor) agonists in 
3T3-L1 adipocytes decreases adiponectin mRNA 
synthesis, and this effect is not present when blockers 
of this adrenergic receptor are administered 
beforehand.43 
Similar to leptin, adiponectin regulates blood pressure 
through a centrally-mediated system.44 Intravenous 
adiponectin infusions lead to dose-dependent decrease 
in blood pressure and sympathetic activity in mice with 
a similar effect, but with ten times lower doses with 
intrathecal administration.44 These studies provide 
strong evidence of the adiponectin-sympathetic 
nervous system relationship both centrally and 
peripherally. 
Hypoadiponectinemia is strongly associated with 
insulin resistance and consequent diabetes, and a part 
of this connection might lie in the regulation of insulin 
signaling and oxidative stress, autophagy and 
mitophagy via adiponectin.45 Ahlstrom et al. showed 
that adiponectin induces autophagy, which attenuates 
high insulin/high glucose-induced endoplasmic 
reticulum stress and improves insulin sensitivity.45 Liu 
et al. showed that in a murine model of obesity and 
insulin resistance induced by high-fat diet, adiponectin 
stimulates skeletal muscle autophagy and antioxidant 
potential, which in turn reduces insulin resistance.46 An 
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in vitro study by Ren et al. conducted in murine C2C12 
myoblasts showed that adiponectin has a moderate 
regulatory role in oxidative stress-induced mitophagy 
and suppresses apoptosis.47 
 
 
Clinical studies of adiponectin in hypertension 
The relationship between obesity and hypertension 
provided an impetus for further research of the effects 
of individual adipokines on blood pressure. A large 
number of clinical studies analyzed the relationship 
between plasma adiponectin concentration and 
hypertension. A review of the most important clinical 
studies is provided in the following text. 
Adamczak et al. were the first to show in 2003 that 
plasma adiponectin concentration is significantly 
decreased in essential (primary, idiopathic) 
hypertension in comparison with normotensive subjects 
with a similar body mass index.48 Iwashima et al. 
demonstrated that hypoadiponectinemia is a risk factor 
for hypertension independently of insulin resistance 
and diabetes.49 Further research showed that there is an 
inverse correlation of plasma adiponectin concentration 
with systolic and diastolic blood pressure and also that 
an inverse correlation exists between plasma 
adiponectin concentration and future risk of developing 
hypertension in a prospective five-year study.50 
However, the interrelationship between plasma 
adiponectin and systolic and diastolic blood pressure is 
not simple and unambiguous. Contrary to previously 
mentioned results on the effects of adiponectinemia on 
hypertension, Murakami et al. did not demonstrate a 
significant difference in adiponectinemia in three 
populations of rural Japanese subjects between 
normotensives and essential hypertension patients 
without insulin resistance, but only between those with 
essential hypertension and concurrent insulin 
resistance.51 Another study also concluded that there is 
no significant association of plasma adiponectin 
concentration and systolic and diastolic blood pressure 
in a population of over 1300 children aged 9 to 16 
years.52 A similar study including 196 children aged 12 
to 18 also did not found any correlation of adiponectin 
with blood pressure or insulin resistance.53 A Chinese 
study which enrolled over 2000 adults found an inverse 
relationship of adiponectin with diastolic but not 
systolic blood pressure.54 As an antithesis to a Chinese 
prospective study which established a predictive role of 
adiponectin in developing hypertension Danish 
Copenhagen City Heart Study did not find such 
predictive role for adiponectin, but established one for 
leptin.50, 55 British Women’s Heart and Health Study, a 
study on a group of 500 older women, did not find an 
association of adiponectin and systolic or diastolic 
blood pressure. What is especially interesting is that 
this association was not present even for the HMW 
multimer, which is today considered the most 
biologically active adiponectin multimer.56 Another 
interesting study is that by Imatoh et al., which was one 
of the first prospective studies on the relationship of 
adiponectin and hypertension.57 This study found a 
decreasing trend in systolic and diastolic blood 
pressure as plasma adiponectin concentration quartile 
increased, and a logistic regression model adjusted for 
main risk factors showed that subjects in the lowest 
quartiles of plasma adiponectin concentration have a 3 
to 4 times greater risk for hypertension. 
A meta-analysis by Kim et al. is probably the most 
important study on adiponectin and hypertension. This 
meta-analysis included 48 studies (of which 5 
prospective) with a total of 17 598 subjects (of which 
8220 hypertensives).58 The conclusion of the meta-
analysis was that subjects with hypertension have a 
lower plasma adiponectin concentration compared to 
normotensive subjects. Also, an increase in adiponectin 
concentration of 1 mg/L increased the odds of 
hypertension by 6%. A year after the publication of this 
study, our group published a paper which did not show 
a difference in plasma adiponectin concentration 
between normotensives and hypertensives with normal 
renal function.59 Taking into account the heterogeneity 
of studies included in this meta-analysis and the fact 
that over a fourth of the studies did not find an 
association of adiponectin and hypertension, the 
question arises of whether this association is the same 
in all populations and stages of hypertension and across 
the whole cardiometabolic continuum. This is 
especially interesting when noting that Mallamaci et al. 
found a positive association of adiponectin and 
hypertension.60 
The results of the Dallas Heart Study, which examined 
the role of adiponectin and hypertension in 1233 
initially normotensive subjects from the general United 
States population, followed up for a median of 7 years, 
showed that 32% of subjects developed hypertension, 
and adiponectin levels were associated with a 19% 
reduction in the risk of incident hypertension 
independent of body fat distribution.61  
Adiponectin gene (ADIPOQ) single nucleotide 
polymorphisms (SNPs) have also been implicated in 
pathophysiology of hypertension. The relationship 
between ADIPOQ SNPs and hypertension is especially 
interesting given that around 30% to 70% of variance 
in plasma adiponectin concentration has a background 
in genetic differences.62  Briefly, one meta-analysis 
which included 12 studies with 3358 hypertensives and 
5121 controls in an evaluation of the association of two 
ADIPOQ polymorphisms (T45G and G276T) with 
hypertension risk and 11 studies (with a total of 3053 
subjects) in an evaluation of between-genotype changes 
of adiponectin and/or blood found that mutation in 
locus G276T was associated with increased plasma 
adiponectin concentration and blood pressure, 
especially in hypertensive patients.63 A recent study by 
Jhuo et al. which examined the association of ADIPOQ 
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SNP T94G and resistant hypertension in young-onset 
patients reported that this SNP was associated with 
around 2.8 times higher odds for resistant 
hypertension.64 An especially interesting hypothesis is 
that different polymorphisms might predispose to 
different adiponectin multimer profiles, but, as far as 




Adiponectin and blood pressure, as well as adiponectin 
and hypertension, seem to be closely associated. 
Protective effects and risk-lowering effects of 
adiponectin are contrary to most other frequently 
researched adipokines and make adiponectin an 
interesting research target and a potential future 
therapeutic target. Well-designed experimental and 
clinical studies should be conducted evaluating 
potential mechanisms via which adiponectin might be 
used as a therapeutic target, most importantly those 
involving increasing insulin sensitivity and lowering 
blood pressure which may play an important role in 
diabetes and hypertension therapy, respectively. 
Because of the apparent great biological importance of 
adiponectin, heralded by, among others, high plasma 
concentration and the association with blood pressure, 
but also due to the controversial and mutually-contrary 
results from different studies on differing populations 
found in the literature, it will be important to assess the 
association of adiponectin with blood pressure and 
hypertension in well-designed prospective studies with 




The text is mostly adapted from the Introduction of the 
doctoral thesis of the author (VI) titled „Association of 
adiponectin gene polymorphisms with blood pressure 
in persons with normal kidney function” defended in 
September 2015 and also includes a review of studies 
published after this date. Neither this thesis or parts of 
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